- Home
- EWTX
as 03-28-2025 4:00pm EST
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 2.3B | IPO Year: | 2021 |
| Target Price: | $45.38 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.90 - $38.12 | Next Earning Date: | 03-03-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Edgewise Therapeutics Inc. (EWTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| KOCH KEVIN | EWTX | President and CEO | Mar 7 '25 | Sell | $30.00 | 100 | $3,000.00 | 14,478 | |
| KOCH KEVIN | EWTX | President and CEO | Feb 5 '25 | Sell | $30.58 | 9,536 | $287,315.62 | 14,478 | |
| Derakhshan Behrad | EWTX | Chief Business Officer | Feb 5 '25 | Sell | $30.03 | 10,000 | $300,300.00 | 16,837 | |
| Russell Alan J | EWTX | Chief Scientific Officer | Feb 5 '25 | Sell | $30.07 | 9,215 | $276,776.12 | 14,863 | |
| Donovan Joanne M. | EWTX | CMO | Jan 28 '25 | Sell | $27.63 | 25,000 | $690,657.50 | 16,358 |
Latest Edgewise Therapeutics Inc. News
EWTX Breaking Stock News: Dive into EWTX Ticker-Specific Updates for Smart Investing
PR Newswire
5 days ago
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time
Business Wire
20 days ago
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference
Business Wire
a month ago
Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025
MT Newswires
a month ago
Edgewise Therapeutics Reports Wider-Than-Expected Q4 Net Loss
Business Wire
a month ago
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Insider Monkey
a month ago
Should You Invest in Edgewise Therapeutics (EWTX)?
MT Newswires
2 months ago
Edgewise Therapeutics Insider Sold Shares Worth $300,300, According to a Recent SEC Filing
MT Newswires
2 months ago
Edgewise Therapeutics Insider Sold Shares Worth $287,316, According to a Recent SEC Filing
Compare EWTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EWTX Edgewise Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.